Averting the #postantibiotic era: successful use of #meropenem/vaborbactam for #carbapenem-resistant #Serratia marcescens and #Enterobacter aerogenes bacteraemia in a haemodialysis patient (J Antimicrob Chemother., abstract)

[Source: Journal of Antimicrobial Chemotherapy, full page: (LINK). Abstract, edited.]

Averting the post-antibiotic era: successful use of meropenem/vaborbactam for carbapenem-resistant Serratia marcescens and Enterobacter aerogenes bacteraemia in a haemodialysis patient

Sarah C J Jorgensen, Philip McDonald, Ryan P Mynatt, Jason M Pogue, Stephen A Lerner, Sorabh Dhar, Hossein Salimnia, Michael J Rybak

Journal of Antimicrobial Chemotherapy, dky346, https://doi.org/10.1093/jac/dky346

Published: 04 September 2018


The prevalence of carbapenem-resistant Enterobacteriaceae (CRE) has increased dramatically over the past two decades, fuelling speculation that we are nearing the ‘post-antibiotic era’ and attesting to the critical need for novel antibiotics with activity against MDR pathogens.1 In 2015 the US FDA approved ceftazidime/avibactam for the treatment of complicated urinary tract infections (cUTIs) and complicated intra-abdominal infections caused by MDR Gram-negative bacteria.2 The introduction of ceftazidime/avibactam represented significant progress in the treatment of CRE, with accumulating real‐world data demonstrating improved efficacy and safety compared with older, more toxic antibiotics.3–5However, treatment failure rates as high as 30%–50% have been…



Issue Section: Research letter

© The Author(s) 2018. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please email: journals.permissions@oup.com.

This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model)

Keywords: Antibiotics; Drugs Resistance; Carbapenem; Serratia marcescens; Enterobacter aerogenes; Bacteremia; Meropenem; Vaborbactam.


Published by

Giuseppe Michieli

I am an Italian blogger, active since 2005 with main focus on emerging infectious diseases such as avian influenza, SARS, antibiotics resistance, and many other global Health issues. Other fields of interest are: climate change, global warming, geological and biological sciences. My activity consists mainly in collection and analysis of news, public services updates, confronting sources and making decision about what are the 'signals' of an impending crisis (an outbreak, for example). When a signal is detected, I follow traces during the entire course of an event. I started in 2005 my blog ''A TIME'S MEMORY'', now with more than 40,000 posts and 3 millions of web interactions. Subsequently I added an Italian Language blog, then discontinued because of very low traffic and interest. I contributed for seven years to a public forum (FluTrackers.com) in the midst of the Ebola epidemic in West Africa in 2014, I left the site to continue alone my data tracking job.